Aaron Cowen’s Viking Therapeutics VKTX Stock Holding History

Aaron Cowen’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-60,000	Closed	-$999K	–	111
2023 Q1	$999K	Buy	+60,000	New	+$620K	0.04%	80

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Aaron Cowen's VKTX Position: Q2 2023 in Review

Aaron Cowen sold out of Viking Therapeutics (VKTX) in Q2 2023, closing a stake of 60,000 shares — an estimated $999K sold.

Aaron Cowen first reported a position in VKTX in Q1 2023 and held it in 1 quarter. The position peaked at $999K in Q1 2023. 193 funds tracked by Wall St. Rank hold VKTX as of Q2 2023.

Aaron Cowen reported no remaining Viking Therapeutics position as of Q2 2023 after selling out during the quarter.
Aaron Cowen sold 60,000 Viking Therapeutics shares in Q2 2023, an estimated $999K.
Aaron Cowen first reported a position in Viking Therapeutics in Q1 2023 and held it in 1 quarter.
Aaron Cowen's Viking Therapeutics position peaked at $999K in Q1 2023.
193 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2023.

Based on Suvretta Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.